

Announcement No. 7/2009

To NASDAQ OMX Copenhagen and the press

Vedbaek, 1 April 2009

Exiqon A/S – Minutes of annual general meeting 2009

The annual general meeting of Exiqon A/S has been held today 1 April 2009 on the Company's address at Skelstedet 16 2950 Vedbaek where the general meeting resolved:

1. To approve the audited annual report,
2. To settle the losses of the year in Exiqon A/S of DKK 63.1 million by transfer to next year,
3. To re-elect Thorleif Krarup, Erik Walldén, Michael Nobel and Per Wold-Olsen as members of the supervisory board, and to elect Douglas S. Harrington as a new member of the supervisory board,
4. To re-appoint Deloitte Statsautoriseret Revisionsaktieselskab as the company's auditor, and
5. To amend the Register of Shareholders' address in the Articles of Association.

On a meeting held immediately afterwards the general meeting the supervisory board elected Thorleif Krarup as chairman of the supervisory board and Erik Walldén as vice chairman of the supervisory board. The composition of the supervisory board is, hereafter, as follows:

Thorleif Krarup, chairman
Erik Walldén, vice chairman
Michael Nobel
Per Wold-Olsen
Douglas S. Harrington

Additional information:

Lars Kongsbak, CEO, phone +45 45 66 08 88 (cell: +45 40 90 21 01)
Hans Henrik Chrois Christensen, CFO, phone +45 45 66 08 88 (cell: +45 40 90 21 31)

About Exiqon

Exiqon is a biotech company with activities in three business areas where the company's technologies provide a competitive advantage: sale of diagnostic tests (Exiqon Diagnostics), sale of innovative research products for miRNA research (Exiqon Life Sciences), and in contract research together with pharmaceutical companies (Exiqon Pharma Services). Exiqon is dedicated to personalizing the treatment selection for cancer patients. The aim is to optimize the use of existing medicine and avoid unnecessary and non-effective treatment. By using molecular diagnostic tests that analyse the genetic profile of each patient's tumor, treatment selection can be optimized for individuals. Exiqon is uniquely positioned to develop such new diagnostic tests. Exiqon already markets diagnostic tests that based on fresh tumor tissue enable doctors to test whether their patients are resistant to one or more of the chemotherapies offered to treat these patients and help them select an efficacious treatment. Exiqon's new molecular diagnostic products are based on the LNA™ technology that enables testing on fixed tissue. The first molecular diagnostic product was launched in December 2008. A number of new products will follow in the years ahead. Using the LNA™ technology is what has allowed Exiqon to establish a position for itself as one of the market's leading providers of research products for gene expression analysis. These research products are used by university scientists and in the pharmaceutical industry around the world to make groundbreaking discoveries about the correlation between gene activity and the development of various diseases. Exiqon is also collaborating with pharmaceutical companies in their effort to develop new medicines based on biomarkers (Personalized Medicine). Exiqon has more than 200 employees and is listed on the NASDAQ OMX in Copenhagen and categorized as a biotech company (Small Cap+). Exiqon is financed until expected breakeven in 2011.

Disclaimer

Forward-looking statements:

This announcement contains forward-looking statements regarding Exiqon's potential future development and financial performance and other statements which are not historical facts. Such statements are made on the basis of assumptions and expectations which, to the best of Exiqon's knowledge, are reasonable and well-founded at this time, but which may prove to be erroneous. Exiqon's operations are characterized by the fact that its actual results may deviate significantly from that described herein as anticipated, believed, estimated or expected.